Pharmaceuticals

The appointment of a supply chain veteran isn't just HR news; it's the key to unlocking a global market for a new heart drug and a lesson in modern strategy.

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

In a major show of biotech investor confidence, Talawar Therapeutics is going public via a SPAC merger, securing $285M to advance its novel bispecific antibody.

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.

A rare disease drug's EU approval is revoked over 'misleading' data, impacting patients and signaling a new era of strict regulatory scrutiny for pharma giants.

New data on a once-weekly drug and a novel combination therapy signal a major shift in treating achondroplasia, moving the focus from height to quality of life.

As pharma giants battle with blockbuster drugs, one company is betting on a simple, non-systemic hydrogel. Is this the future of weight management?

A landmark FDA decision on Trodelvy reshapes metastatic TNBC care, offering new hope while directly confronting deep-seated racial disparities in treatment.

While national HIV rates fall, a new Johns Hopkins report reveals how a decade of policy neglect is fueling a devastating surge among Latino communities.

Valneva's latest AGM wasn't just procedural. A new expert Chair and key operational shifts reveal a company doubling down on its late-stage vaccine strategy.

Nomic Bio and the HESI OASIS Consortium partner to map liver toxicity using proteomics, fueling AI models to make drug development safer and more ethical.

Oramed leverages a strategic pivot into a diversified operator, seeing massive gains from its Alpha Tau stake and securing entry into the Russell 2000 index.

As MAPS announces its 2027 summit, the psychedelic field grapples with a critical question: can its visionary promise survive the harsh pressures of reality?

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

An award for an AI search tool seems routine, but Ask Ella signals a deeper rewiring of the life sciences industry, turning data drudgery into strategic speed.